Works by Dagogo‐Jack, Samuel


Results: 107
    1
    2
    3
    4

    Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
    By:
    • Kim, Joseph M.;
    • Bhatt, Deepak L.;
    • Dagogo‐Jack, Samuel;
    • Cherney, David Z. I.;
    • Cosentino, Francesco;
    • McGuire, Darren K.;
    • Pratley, Richard E.;
    • Liu, Chih‐Chin;
    • Cater, Nilo B.;
    • Frederich, Robert;
    • Mancuso, James P.;
    • Cannon, Christopher P.
    Publication type:
    Article
    5

    Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
    By:
    • Corbin, Karen D.;
    • Dagogo‐Jack, Samuel;
    • Cannon, Christopher P.;
    • Cherney, David Z.I.;
    • Cosentino, Francesco;
    • Frederich, Robert;
    • Liu, Jie;
    • Pong, Annpey;
    • Lin, Jianxin;
    • Cater, Nilo B.;
    • Pratley, Richard E.
    Publication type:
    Article
    6

    Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
    By:
    • Segar, Matthew W.;
    • Kolkailah, Ahmed A.;
    • Frederich, Robert;
    • Pong, Annpey;
    • Cannon, Christopher P.;
    • Cosentino, Francesco;
    • Dagogo‐Jack, Samuel;
    • McGuire, Darren K.;
    • Pratley, Richard E.;
    • Liu, Chih‐Chin;
    • Maldonado, Mario;
    • Liu, Jie;
    • Cater, Nilo B.;
    • Pandey, Ambarish;
    • Cherney, David Z. I.
    Publication type:
    Article
    7
    8
    9
    10

    Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 3, p. 530, doi. 10.1111/dom.13116
    By:
    • Dagogo‐jack, Samuel;
    • Liu, Jie;
    • Eldor, Roy;
    • Amorin, Guillermo;
    • Johnson, Jeremy;
    • Hille, Darcy;
    • Liao, Yuqin;
    • Huyck, Susan;
    • Golm, Gregory;
    • Terra, Steven G.;
    • Mancuso, James P.;
    • Engel, Samuel S.;
    • Lauring, Brett
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    32
    33
    34
    35

    A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program.

    Published in:
    Journal of the Endocrine Society, 2019, v. 3, n. 9, p. 1663, doi. 10.1210/js.2019-00069
    By:
    • Srinivasan, Shylaja;
    • Jablonski, Kathleen A;
    • Knowler, William C;
    • Dagogo-Jack, Samuel;
    • Kahn, Steven E.;
    • Boyko, Edward J;
    • Bray, George A;
    • Horton, Edward S;
    • Hivert, Marie-France;
    • Goldberg, Ronald;
    • Chen, Ling;
    • Mercader, Josep;
    • Harden, Maegan;
    • Florez, Jose C;
    • Group, Diabetes Prevention Program Research
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50